Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the Select Trial

Authors

Donna H Ryan
Ildiko Lingvay
John Deanfield
Steven E Kahn
Eric Barros
Bartolome Burguera
Helen M Colhoun
Cintia Cercato
Dror Dicker
Deborah B Horn
G Kees Hovingh
Ole Kleist Jeppesen
Alexander Kokkinos
A Michael Lincoff
Sebastian M Meyhöfer
Tugce Kalayci Oral
Jorge Plutzky
André P van Beek
John P H Wilding
Robert F Kushner

Publication Date

7-1-2024

Journal

Nature Medicine

Abstract

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (

Keywords

Humans, Glucagon-Like Peptides, Weight Loss, Obesity, Male, Female, Middle Aged, Body Mass Index, Adult, Aged, Treatment Outcome, Double-Blind Method, Cardiovascular Diseases

Comments

Supplementary Materials

PMID: 38740993